Skip to content
sellWeak cluster of 610b5-1 plan

Patrick Lamy sold $29k of AKRO

Senior VP, Commercial Strategy at Akero Therapeutics, Inc.. 1,000 shares at an average of $29.13, traded Dec 16, 2024, filed Dec 18, 2024.

Warning score
15
Value
$29k
1,000 shares
Holdings after
34,258
-3% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet

Score components

  • Role
    Officer
    +15
  • Trade size
    $29k at market
    +5
  • Share of holdings sold
    Sold 2.8% of holdings
    0
  • Cluster
    6 insiders selling within 14 days
    +15
  • 10b5-1 plan
    Pre-scheduled under a 10b5-1 plan
    -20

What happened after comparable sells

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Rows in this filing

Every transaction in Form 4 0000950170-24-138149, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Dec 16, 2024AGrant or award
Common Stock10b5-1
+17,400$0.00$035,258Dec 18, 2024
Dec 16, 2024SOpen-market sale
Common Stock10b5-1
-1,000$29.13$29k34,258Dec 18, 2024
Dec 16, 2024AGrant or award
Stock Option (Right to Buy)derivative10b5-1
+52,100$0.00$052,100Dec 18, 2024

Related signals

Other insiders at Akero Therapeutics, Inc. and this insider’s other filings.

ScoreSideCompanyInsiderValueSharesFiled
51ModeratebuyAKRO
Akero Therapeutics, Inc.
G. Walmsley Graham
director
$8.8M200,000
12Weaksell 610b5-1AKRO
Akero Therapeutics, Inc.
Catriona Yale
Chief Development Officer
$448k10,000
30Weaksell 6AKRO
Akero Therapeutics, Inc.
Timothy Rolph
Chief Scientific Officer
$23k516
42Moderatesell 6AKRO
Akero Therapeutics, Inc.
William Richard White
Chief Financial Officer
$30k676
35Weaksell 6AKRO
Akero Therapeutics, Inc.
Catriona Yale
Chief Development Officer
$28k614
40Moderatesell 6AKRO
Akero Therapeutics, Inc.
Jonathan Young
Chief Operating Officer
$27k607
49Moderatesell 6AKRO
Akero Therapeutics, Inc.
Andrew Cheng
President and CEO
$78k1,738
45Moderatesell 610b5-1AKRO
Akero Therapeutics, Inc.
Andrew Cheng
President and CEO
$1.3M30,000
14Weaksell 610b5-1AKRO
Akero Therapeutics, Inc.
Timothy Rolph
Chief Scientific Officer
$557k12,500
2Weaksell 610b5-1AKRO
Akero Therapeutics, Inc.
Patrick Lamy
Senior VP, Commercial Strategy
$48k1,000

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Patrick Lamy sold $29k of AKRO | InsiderTell